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Surntnary 
CD4 T  cell receptors (TCRs) recognize antigenic peptides presented by self major histocom- 
patibility complex (MHC) class II molecules as well as non-self MHC class II molecules. The 
TCR.s can also recognize endogenous retroviral gene products and bacterial toxins known col- 
lectively as superantigens (SAGs) that act mainly on the V{3 gene segment-encoded portion of 
the V{3 domain; most SAGs also require MHC class II for presentation. We have studied the 
interaction of the TCR from a well-characterized CD4 T  cell line with SAGs by mutational 
analysis of its VI3 domain. This appears to separate viral (v)SAG from bacterial (b)SAG recogni- 
tion. T  cells having a TCR. with a glycine to valine mutation in amino acid residue 51 (G51V) 
in complementarity determining region 2 of the TCIL V[3 domain fail to respond the bSAGs 
staphylococcal entertoxin B (SEB), SEC1, SEC2, and SEC3, whereas they retain the ability to 
respond to non-self MHC class II molecules and to foreign peptides presented by self MHC 
class II molecules. It is interesting to note that T  cells expressing mutations of both G51V and 
G53D of V[3 regain the response to SEB and partially that to SEC1, but do not respond to 
SEC2 and SEC3, suggesting that different bacterial SAGs are viewed differently by the same 
TCR. These results are surprising,  because it has been generally believed that SAG recognition 
by T  cells is mediated exclusively by hypervariable region 4 on the exposed, lateral face of the 
TCR V[3 domain. Response to the vSAG Mtv-7 was generated by mutation in V[3 residue 24 
(N24H),  confirming previously published data.  These data show that the vSAG Mtv-7 and 
bSAGs are recognized by different regions of  the TCR V[3 domain. In addition, various bSAGs 
are recognized differently by the same TC1L. Thus, these mutational data, combined with the 
crystal structure of the TCR ~3 chain, provide evidence for distinct recognition sites for vSAG 
and bSAG. 
1  The  TC1L can recognize superantigens (SAGs) derived 
.IL from bacterial or endogenous retroviral genes (bSAG 
or vSAG). Unlike conventional antigen recognition, where 
the CDR3 regions of the TCR ~  and [3 chains play a criti- 
cal role, response to these substances involves primarily the 
V[3 gene segment-encoded portion of the V[3  domain of 
the TCR. As 2-10% ofT cells express the product of a given 
V[3 gene segment, SAGs stimulate T cells of many different 
specificities. Recognition ofbSAGs and vSAGs by the TCR 
is believed to involve regions distinct from the antigen rec- 
ognition site,  comprising the  CD1L  1,  2,  and 3  loops  of 
both chains of the TCR, as predicted earlier (1). Many re- 
ports have shown that a region known as hypervariable re- 
gion 4 (HVR4) between the E and F strands  of the TCR. 
V[3 domain is a crucial site for SAG recognition, but is not 
1Abbreviations used in this paper: bSAG, bacterial superantigen; CA, conal- 
bumin; HVR4, hypervariable region 4; SAG, superantigens; SEB, Staph- 
yloccal enterotoxin B; TSST-1, toxic shock syndrome toxin 1. 
involved in responses  to foreign peptide-.self MHC (2-4). 
Although several reports (5-8) suggest that TCI~ sites other 
than the HV1L4 of the TCR V[3 domain affect recognition 
of SAGs, all of these studies nevertheless point to the lateral 
face of V[3 as the most crucial factor in SAG recognition. 
Recently, the x-ray crystal structure of the bSAG Staphylo- 
coccal enterotoxin B  (SEB) bound to  the  human MHC 
class II HLA-DR1 molecule has been solved (9). This shows 
that SEB binds to the or-helical region of the HLA-DR ot 
chain; if the TCR V[3 domain recognizes this complex, the 
TCR Voc domain must sit on top of the or-helical region of 
the HLA-DR [3 chain. In fact, two studies showed that the 
V region of the TCR ct chain interacts with the or-helical 
region of the HLA-DR [3  chain during SEB  recognition 
(10, 11). Previously, we have reported that during non-self 
MHC recognition, the CDR1 and/or CDR2 of the TCR 
Vet domain interacts with the or-helical region of the I-A ot 
chain, leading us to conclude that the TCR [3 chain must 
interact with the I-A [3 chain (12). This TCtL-MHC inter- 
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TCK-SEB--MHC interaction. 
In this report, we have examined SAG recognition by 
the TCtL of  the well-characterized CD4 T cell line D10.G4.1 
(13). We have examined the role of several amino acid res- 
idues,  including  those  in the  CDR1  and  CDR2  equiva- 
lents  of the  TCR  [3  chain,  in recognition  of both bSAG 
and the vSAG Mtv-7, as well as in recognition of foreign 
peptide-self MHC  and non-self MHC  class II molecules. 
One mutation at residue 51 from glycine to valine (G51V) 
in CD1L2 of the TCK V~3 domain, which does not affect 
non-self MHC  recognition,  has a  profound  effect on re- 
sponses to the bSAGs SEB, SEC1,  SEC2,  and SEC3.  It is 
interesting to note that T  cells expressing this mutation plus 
that of a neighboring residue (D 10etG51V,G53D[3), recover 
responsiveness  to  SEB  and  SEC1,  but  not  to  SEC2  and 
SEC3, whereas cells having D10etG53DI$ respond well to 
all bSAGs. In agreement with the earlier studies (2), a mu- 
tation at residue 24 (N24H) of the TCK [3 chain results in 
a gain of response to the vSAG Mtv-7.  Tranffectants ex- 
pressing mutations in both Vet and VI3 retain the character- 
istic responses of each chain when stimulated separately ei- 
ther with non-self MHC molecules or with SAG. 
Materials and Methods 
Animals.  The mice used in these studies were obtained from 
The  Jackson Laboratory (Bar Harbor, ME) or from the Core Mouse 
Breeding Facility maintained at Yale. The following mouse strains 
were used: B10.BI~ (I-Ak), AKK/J (H-2  k, Mls-la), and C57BL/6J 
(I-^b). 
Antibodies.  The following mAbs were used: monoclonal anti- 
CD3e YCD3-1 (14) and monoclonal anti-CD4 GK1.5 (15). 
Cell Lines.  The T cell line D10.G4.1  (13) has been described 
previously. The class II MHC-expressing cell line CH27 has been 
described previously (16). The 4G4, TCIL 0t and 13 negative T cell 
hybridoma was kindly provided by Ed Palmer (Basel Institute for 
Immunology, Switzerland).  This  cell line  allows  expression  of 
transfected ct/13 heterodimeric  TCR. 
Mutagenesis of TCR ~ Chain.  Mutagenesis of a TCK 13 chain 
cDNA construct  was performed using the overlapping extension 
method (17) with the PCK. PCK conditions were 25 cycles 
of 1 min at 94~  1 rain  at  55~  and  2  rain  at 72~  using 
wild-type D10 TCtL 13 chain  cDNA as a template DNA. The 
following  PCK primers were used.  5' primer GTATCCTGA- 
GAGGAAGCATG and 3' primer CTGCTCGGCCCCAGGCC- 
TCT were the two external primers to generate  the mutation. 
Mutagenic  primers were  as  follows:  N24H,  coding  sequence, 
GAGCTGTCACCAGACTAATA, noncoding sequence,  TAT- 
TAGTCTGGTGACAGCTC; H29E, coding sequence, TGTAAT- 
CAGACTAATAACGAGAACAACATG, noncoding sequence, 
CATGTTGTTCTCGTTATTAGTCTGATTACA;  G51V, cod- 
ing sequence, CATTATTCATATGTTGCTGC~AGCACT,  non- 
coding  sequence,  AGTACTGCCAGCAACATATGAATAATG; 
G53D,  coding sequence,  TCATATGGTGCTGACAGCACT- 
GAGAAA, noncoding sequence, TTTCTCAGTGCTGTCAG- 
CACCATATGA; and G51V/G53D,  coding sequence, CATTAT- 
TCATATGTTGCTGACAGCACTGAG,  noncoding  sequence, 
CTCAGTGCTGTCAGCAACATATGAATAATG. 
Production and Analysis of Transfectants.  Transfected T  cell hy- 
bridomas  expressing  mutant VI38.2 chains  were  generated  and 
analyzed as previously described (12). 
Peptides and SAGs.  Peptides were synthesized as described (18). 
Purified  SEB, SEC1,  SEC2,  and  SEC3  were  purchased  from 
Toxin Technology, Inc. (Sarasota, FL). 
Analysis of TCellResponses.  Experiments  were  carried  out 
on 96-weU flat-bottom plates in 200  ~l/well with  1-5  ￿  104 
TCK transfectants and APCs.  When  spleen  cells were used  as 
APCs, "1-3 ￿  10  s cells/well were used. When B cell lines were 
used as APCs,  -',1-5 ￿  104 cells/well  were used. These condi- 
tiom produced the most optimal stimulation  without increasing 
nonspecific  IL-2 secretion.  The TCK transfectants were incu- 
bated for 24 h, and the IL-2 content of the supernatants was mea- 
sured by a CTLL assay. 
CTLL-2 Stimulation Assays.  All IL-2 assays  were performed in 
96-well  flat-bottom plates with CTLL-2 responder  cells. 50 0.1/ 
well of supernatant  from experimental  plates was transferred to a 
clean plate, frozen in the liquid nitrogen freezer, and thawed to 
kill any viable cells. Approximately 5-10 ￿  103 CTLL cells/well 
50 ~1 were added and allowed to proliferate for 20 h; they were 
then pulsed  with high  specific activity  [3H]thymidine  (1  I~Ci/ 
well) for 4 h, and harvested onto falter mats. The incorporated ra- 
dioactivity was counted on a B-plate counter. 
Results 
The DlO TCR and the Rationale  for Mutagenesis.  The  TCK 
of the  cloned T  cell line  D10  recognizes a  peptide frag- 
ment of conalbumin (CA)  (18) presented by the selfMHC 
molecule  I-A  k,  as  well  as  the  non-self MHC  molecules 
[_Ab,v,p,q, and d (19,  20) and the bSAGs SEB, SEC1,  SEC2, 
and  SEC3  (1).  In  an  earlier  study,  we  showed  that  the 
NH2-terminal half of the TCR Vet domain played a critical 
role in the recognition ofnon-selfMHC class II I-A mole- 
cules (12).  These studies suggested that the CDK1 and/or 
CDR2  equivalent  of the  Vet  domain  interacts  with  the 
a-helical region of the I-A et chain. We have identified Vet 
residue  30  as  the  primary distinction  between  these  two 
TCR. molecules (Hong, S.-C., D.B. Sant'Angelo, G. Water- 
bury, and C.A. Janeway, Jr., manuscript submitted for pub- 
lication). 
To further analyze the individual amino acids responsible 
for the recognition of SAGs, we initiated a mutational anal- 
ysis of the D10 TCR V[3 domain. The V domain of the 13 
chain of the D10 TCR is encoded by V[38.2  (12). Because 
mice have three closely related V[38 genes, we used the nine 
amino  acid  differences  between  TCR  VI38.1  and  TCR. 
VI38.2 to guide our mutagenesis strategy. These differences 
are  located  between  the  NHz  terminus  and  CDK1,  in 
CDK1  residues 30 and 31,  in CDR2 residues 51  and 53, 
and in strand F between CDR.2 and CDR.3 (Table 1). The 
majority  of T  cells  expressing  TCK  V[38.1  recognize  a 
vSAG, Mtv-7, whereas only a small fraction of T  cells ex- 
pressing TCK  V[38.2  do so  (2,  21).  On  the  other hand, 
SEB strongly stimulates T  cells  expressing VI38.2 but only 
weakly  stimulates  T  cells  expressing  TCR.  V[38.1.  It  is 
known that the CD1L3 regions of both Vet and VI3 are in- 
volved in peptide  recognition  (12,  22-24).  Moreover,  as 
CDR3 is thought to lie in the center of the TCR. recogni- 
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Amino acid residue  V[38.1  VJ38.2 
10  S  N 
24  H  N 
CDRI (25-33) 
30  D  N 
31  Y  N 
CDR2 (48-56) 
51  V  G 
53  D  G 
83  S  T 
84  L  P 
88  A  S 
tion  site,  mutations  in  CDR3  are  not  informative  as  to 
SAG recognition (data not shown).  We have therefore fo- 
cused our analysis on mutagenesis of CDR1  and CDR2  of 
the TCR  VJ3 domain. Several independent mutations were 
generated by overlapping PCR mutagenesis (17). The wild- 
type and mutant D10 TCR  ]3 chain cDNAs were cotrans- 
fected with  D10  TCR  ix  chain  cDNA  as  well  as  mouse 
CD4  cDNA  into  a  routine  hybrid  thymoma  called 4G4. 
These transfectants expressed comparable levels of the TCR 
and CD4  molecules as detected by FACS  |  analysis (Table 
2).  All the  transfectants  were  tested  for  their  response  to 
anti-TCR  or anti-CD3 mAb,  to antigen presented by self 
MHC,  to  allogeneic MHC  molecules, and to  both bSAG 
and vSAG. 
vSA G Mtv-7 Is Recognized by Residue 24 which  Contributes 
to HVR4 of the  TCR  V~ Domain.  According to  the  crys- 
tal structure  of the  TCR  VJ38.2  chain  (25),  residue 24  of 
the TCR  J3 chain is adjacent to the HVR4 loop, and is ex- 
posed on the lateral surface ofV[38.2 together with two ad- 
jacent amino acids in HVR4,  73 and 74, that are known to 
affect  Mtv-7  recognition  (Fig.  1  a)  (2).  When  asparagine 
Figure 1.  Space-filling  model of TCR VJ38.2 chain. (a) Space-filling  model of the putative vSAG (Mtv-7) binding face of the V[38.2 domain. Muta- 
tion of  residue 24 confers reactivity to Mtv-7 on this V[3, when mutation at residues 51 and 53 affect  responses to SEB and SEC1, 2, and 3. (b) Space-fill- 
ing model of CDR loops facing the MHC-peptide complex showing the amino acid residues examined. (Green) CDR1; (magenta) CDR2; (blue) CDR3i 
and (yellow) HVR4.  (Silver) Mutated amino acids with the residues mutated shown by a number. 
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2413 in the D10 TCR  (Vb8.2) was replaced by the histidine 
(N24H)  found at this position in an inbred mouse, V[38.1, 
reactivity  to  Mtv-7  resulted  (Fig.  2  a).  As  expected,  cells 
bearing the TCR  D10otN24H[3 responded strongly to an- 
tigen,  to SEB,  and to allogeneic MHC  molecules  (Fig.  2, 
b-d).  These  data  confirm  that  recognition  of the  vSAG, 
Mtv-7,  is  mediated  by  the  lateral  face  of HVR4  of the 
TCR V[3 domain. 
Effect of Amino Acids  in  the CDR2 Loop of the  TCR  Vfl 
Domain on Recognition of bSA G.  When  T  cells  expressing 
various mutations in TCR. V[38.2 were tested for their re- 
sponses to the bSAG, SEB, all  T  cells  except those with a 
mutation  in  CDR2  residue  51  (D10otG51VI3)  responded 
equally to SEB  (Fig.  3  a).  Cells  bearing D10otG51V~  re- 
sponded  to  anti-CD3  mAb  stimulation  and  to  allogeneic 
MHC molecules equivalently to D10otD10[3 transfectants, but 
showed a  diminished  sensitivity  to antigenic  peptide  (Fig. 
3, b-d). We also tested other bSAGs that are recognized by 
the  murine  TCR  V[38.2.  As expected,  all  of these bSAGs 
stimulated  transfectants  expressing  D10otD10~,  but  none 
stimulated transfectants expressing the mutant D10otG51V[3; 
this suggests that all of these recognition events are affected 
..... t  7 
10 
Figure  2.  The  responses of the 
transfectants to various stimuli. Mu- 
tation  N24H  confers reactivity to 
Mtv-7 (a) but does not alter recogni- 
tion of SEB (b), antigen (c), or allo- 
geneic MHC class II (d). (a) Mtv-7 
response of the  transfectants. Re- 
sponses of transfectants to  Mtv-7  + 
strain AKR/J (Q, .) and to Mtv-7- 
strain B10.BR (O, V1). (b) SEB re- 
sponse of the transfectants presented 
by 10  s CH27 cells. (c) Response of 
the transfectants to an antigenic pep- 
tide of conalbumin (CA) presented 
by 105 CH27 cells. (d) Response of 
the transfectants to non-self class II 
MHC I-A  b, stimulated with spleen 
cells from C57BL/6J mice. 1-3  ￿ 
10  4  transfectants were used for the 
IL-2 release assay. 
by this mutation  (Fig. 3, e-g). We also tested many other T 
cells  expressing  other  mutant  TCR  [3  chains,  and  all  of 
these responded to SEB as well as to anti-CD3 mAb stimu- 
lation, with the exception of those having the G51V[3 mu- 
tation (Table 2). 
To further analyze this loss of function mutation, T  cells 
expressing  [3  chains  with  double  mutations,  including 
G51V[3, were produced. T  cells expressing the double mu- 
tations  N24H,G51V[3,  and  H29E,G51V[3,  together  with 
the D10 TCR  ot chain,  responded well to anti-CD3 mAb 
stimulation  (Fig.  4  a),  but failed to respond to stimulation 
with SEB (Fig. 4 b). This again confirms the role of G51V[3 
in SEB recognition.  In addition,  T  cells  expressing N24H, 
G51V[3  responded  well  to  Mtv-7  (Fig.  4  c),  segregating 
vSAG and bSAG recognition by the same TCR V[3 domain. 
Differences in the Recognition of bSAGs  by  the Same  TCR. 
T  cells expressing the mutation G51V[3 lost response to all 
the bSAGs tested (Figs.  3 and 4), whereas additional muta- 
tions in other residues  in V[3,  such as the  [3 strand-associ- 
ated N24H,G51VI3 and the CDP,1 loop H29E, G51V[3 did 
not  alter  responses  to  SEB  from those  observed with  the 
original G51V~ mutation. However, when T  cells express- 
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Figure  3.  The  response  of 
transfectants  expressing  the 
D10c~D1013  (0)  or  the  mutant 
D10~xG51V[3  (￿9  TCR  to vari- 
ous  stimuli:  (a)  SEB,  (b)  anti- 
CD3,  (c)  I-A  b  spleen,  (d)  CA 
peptide plus I-A  k spleen cells,  (e) 
SEC1,  (f)  SEC2,  and (g) SEC3. 
Responses  were  elicited  as  in 
Fig. 2.  For anti-CD3  and bSAG 
stimulation,  different amounts of 
anti-CD3  mAb  (YCD3-1)  or 
bSAG were presented by CH27. 
ing a double mutation in CDR2,  replacing residues 51  and 
53  with  those  naturally  found  in  inbred  TCR  V138.1 
(G51V,G53DI3),  the  resulting  transfectants  (D10~G51V, 
G53D[3)  were  found  to have  recovered responses  to SEB 
and  to  high  concentrations  of SEC1,  but  not  those  to 
SEC2  and  SEC3  (Fig.  5).  These  data  again  demonstrate 
that the  CDR2  loop affects the recognition  of all  of these 
bSAGs and that SEB and the SECs are recognized similarly, 
but not identically, by this TCR. 
Responses  to  Allogeneic MHC  Class II Molecules and  to 
bSAG Are Independent Recognition Events  by the Same  TCR. 
We tested whether the TCR  recognizes MHC  class II mol- 
ecules in the same way during responses to allogeneic MHC 
class II molecules and to bSAG. To do so, we made a trans- 
fectant that expresses a  well-characterized  mutant  TCR  et 
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and  13 chain.  The TCR,  AK8:D10aD10[3,  contains  seven 
mutations  in  the  NH2-terminal  half of the  TCR  ~x chain 
that result in a gain of response to I-A  d and a loss of response 
to I-A  b from the original wild-type D10otD1013 TCR  (12). 
We  made  a  transfectant  expressing  this  TCR  cx  chain 
paired with a  [3 chain containing  the  G51V mutation,  and 
tested its reactivity.  This T  cell,  called AK8:D10otG51V[3, 
did not respond to SEB, which is characteristic of the TCR 
[3  chain  mutation  G51V[3,  but  maintained  its  response  to 
anti-CD3  mAb  (Fig.  6,  a  and  b).  In addition,  this  double 
mutant TCR  lost its usual response to I-A  b and gained a re- 
sponse to I-A  d, which is characteristic  of the mutant TCR 
~x  chain  AK8:D10ot  (Fig.  6,  c and  d).  This  suggests  that 
TCR  recognition ofallogeneic MHC  molecules and bSAG 
can occur independently. Table  2.  Transfectants  Tested for their SEB Recognition 
TCR-ot  TCR-I3  SEB response 
MFI of transfectant with 
CD3 response  Anti-TCR  Anti-CD4 
D10  D10  +++  +++  93  117 
D10  N27D  +++  +++  103  100 
D10  N27Q  + + +  + + +  99  110 
D10  N28D  +++  +++  115  88 
D10  N28Q  + + +  + + +  123  87 
D10  H29E  + + +  + + +  197  115 
D10  H29Q  + + +  + + +  ND  ND 
DI0  N30D  + + +  + + +  ND  ND 
D10  N31Y  + + +  + + +  ND  ND 
D10  G51A  + + +  + + +  ND  ND 
D10  G51V  --  +++  131  125 
D10  G53A  + + +  + + +  ND  ND 
D10  G53D  + + +  + + +  147  119 
MFI, mean fluorescence intensity. 
Discussion 
The TCR of the CD4 T cell clone D10.G4.1 recognizes a 
peptide fragment of antigen presented by self MHC class II 
molecules, allogeneic MHC  class II molecules,  and vSAG 
and  bSAG  presented  by self MHC  class  II molecules.  In 
this study, we made site-directed mutations of the V[3 do- 
main in an attempt to understand the nature of these vari- 
ous TCR-ligand interactions. We have shown for each mu- 
tant  tested  in  this  manuscript,  a  retention  of normal  or 
slightly  decreased  recognition  of peptide  plus  self MHC 
class II and/or  of aUogeneic MHC  class II. Thus,  we be- 
lieve that the mutations we have introduced do not signifi- 
cantly perturb MHC class II recognition by this receptor. 
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Figure 4.  The responses of tranffectants expressing the D10etD1013 wild-type receptor (@), the double mutant  N24H,G51VI3  paired with Dl0~x (O) 
and the double mutant H29E,G51VI3 paired with D10~x (0) to various stimuh.  (a) Response  of the transfectants to anti-CD3 mAb CYCD3-1) presented 
by 105 CH27 cells. (b) Response  of the transfectants to SEB presented by 10  s CH27 ceils. (c) Response  of the transfectants to Mtv-7; increasing numbers 
of spleen cells from an Mtv-7 + (AKR/J) mouse were used to stimulate the T cells. 1-3 ￿  104 TCR transfectants were used for the IL-2 release assay. 
1442  Viral/Bacterial Superantigens Are Recognized by Distinct Sites in TCR VI3 a 
20000. 
A  li 
el 
o 
10000. 
O  o. 
io 
o 
SEB 
tDlOI3 
cG51 v 
{C53DI3 
tG5 lV,G53DI3 
O- 
~'m,q  2 
10  !  10 
[SEB] pg/ml 
b 
20000. 
SEC1 
'[" 
10"3-1~  2  10"~10  0  10 1  10 2 
[SECl] ~g/mt 
c 
20000- 
SEC2 
i" 
2 
[SEC2] i.zg/ml 
d 
20000- 
10000, 
SEC3 
0 0 ,0 
[SEC3] gg/ml 
Figure  5.  The  response  of  various 
TCR  transfectants  to  different  bacterial 
superantigens.  Wild-type  D101xD1013 
(O),  D10~xG51V[3  (ll),  D10ecG53D~ 
(Fq),  and  D10aG51V,G53D[3  (A)  were 
stinmlated with the bSAGs SEB (a), SEC1 
(b), SEC2 (c), and SEC3 (d) presented by 
CH27. 
Although the resolution of a crystal structure of this re- 
ceptor-ligand pair should provide major insights into this 
crucial process,  the  variability of both  the  TCR  and  its 
ligands, and the complexity of signaling through the recep- 
tor, require detailed functional analysis of this interaction as 
well.  Moreover, the low affinity of TCR-ligand interac- 
tions (26,  27) suggests  that obtaining such complexes may 
be extremely difficult; indeed, it has been suggested (28-30) 
that binding of the TCR alone is not sufficient for T  cell 
activation, and that a conformational change in the TCR 
may occur as an essential  part of recognition. If this is the 
case, then crystallographic analysis may be even more diffi- 
cult. Therefore, we have approached this problem by mak- 
ing a detailed structure-function analysis of this interaction 
an alternative approach. We have made several TCR mu- 
tations in both Vex and V13 of the D10 TCR to try to de- 
termine  which  residues  mediate  each  interaction  of the 
TCR with its various MHC class II ligands.  Since the Va 
and V[3 CDR3 loops of the TCR are said to interact with 
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different residues of a foreign peptide presented by selfMHC 
molecules,  the  information acquired by CDR3  mutation 
may be limited to the interaction of the TCR with specific 
antigen (22).  To understand TCR-MHC  and TCR-SAG 
interactions, we and others (2, 3, 12, 31, 32) have used mu- 
tational  studies  of CDR1,  CDR2,  and  HVR4,  each  of 
which defines a loop of the o~ and 13 chains of the TCR. 
Here, we will discuss  how our new data may further the 
understanding of this interaction. 
TCR recognition of SAG has  been well characterized. 
Because of the polyclonal in vivo deletion of T  cells  ex- 
pressing certain V[3 chains in mice expressing endogenous 
vSAG and the polyclonal expansion of the same T  cells by 
vSAG and bSAG in vitro and in vivo (33), this recognition 
event is believed to be mediated by specific polymorphic sites 
in the V13 gene segment-encoded part of the 13 chain. Mu- 
tational and transfection studies of TCR support the V13- 
mediated recognition of SAG, especially the role of HVR4 
in  the  TCR  V13  domain  (2-4).  We  have  confirmed the SEB 
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Figure 6.  The response of various TCR transfectants to various stimuli. Transfectants were tested for their response as in Fig. 2. Spleen cells from 
BALB/c mice were used for the allogeneic response to I-A  a. TCR transfectants: (0) D10(xD10[3, (O) AK8:D10(xD10i3; (11) D10(xG51V~, and ([]) 
AK8:D10(xG51V[3. 
finding reported by PuUen  et al.  (2)  that mutation  in resi- 
due 24  (here, N24H)  in the V~ domain can confer Mtv-7 
reactivity  on  a  V~8.2  TCR.  It  is  clear  from  the  crystal 
structure  of the  TCR  V~8.2  chain  (Fig.  1,  a  and  b)  that 
amino  acid residue  24  on the  lateral face of V~  associates 
with residues 73 and 74 which are known to be involved in 
Mtv-7 recognition.  In addition,  these three amino acid res- 
idues are located away from the peptide-MHC  interaction 
site. This may facilitate the direct interaction of Mtv-7 with 
this  site,  as predicted  (1).  Glycosylation of asparagine resi- 
dues 24 and 74 may interfere with the interaction  of wild- 
type TCR  V[38.2 with Mtv-7. Substitution  of one of these 
two asparagine residues seems to be sufficient for Mtv-7 in- 
teraction, since mutation of amino acid residue 74 from as- 
paragine to glutamic acid also restores Mtv-7 reactivity (2). 
Our data on the role of residue 51 of CDR213, shown by 
the mutant G51V, support other studies for TCR  recogni- 
tion ofbSAG (31, 32) that describe evidence that CDR1  or 
CDR2  of the TCR  V[3 chain can affect bSAG recognition. 
The  crystal structure  of the  TCR  V[~8.2  chain  (Fig.  1,  a 
and  b)  clearly  demonstrates  that  amino  acid  residue  51  is 
distant from the amino acids critical for a response to Mtv-7. 
In  addition,  this  amino  acid,  which  is facing towards  the 
peptide-MHC,  is not carried on the lateral face of V~ like 
the  Mtv-7-binding  site.  Recent  crystal  structures  of SEB 
bound  to  HLA-DR1  (9)  and  of toxic  shock  syndrome 
toxin-1  (TSST-1) bound to HLA-DR1  (34) show that SEB 
contacts HLA-DR1  at two sites on the DR1  c~ chain along 
one  edge  of the  peptide-binding  groove.  The  TSST-1- 
binding site, on the other hand,  extends over almost half of 
the peptide-binding site, so that TSST-1 contacts the cl-helical 
region of the DR1  ot chain, the bound peptide,  and part of 
the o~ helix of the DR1  ~  chain. This suggests that TSST-1 
binding  may  be  peptide  dependent.  Furthermore,  it  is 
likely that the recognition of TSST-1-DR1  by the TCR  is 
very  different  from  that  of SEB-DR1  or  peptide-DR1. 
Both of these crystal structures suggest that bSAG recogni- 
tion  by  the  TCR  may be  mediated  by  either  CDR1  or 
CDR2  of the TCR,  rather than the lateral part (HVR4)  of 
the  TCR,  as  has  been  shown  in  responses  to  the  vSAG 
Mtv-7. 
T  cells  expressing  the  double  mutation  N24H~  and 
G51V~ provide further evidence for the separation ofvSAG 
and bSAG recognition by one TCR. In contrast to the wild- 
type D10 TCR,  which responds to many bSAGs including 
SEB,  D10otG51V[3  does not respond to these bSAGs.  On 
the  other  hand,  T  cells  expressing  the  double  mutation 
D10otN24H,G51V[3  gain a  response  to the  vSAG Mtv-7, 
without  gaining response to SEB.  These data are in agree- 
ment with the data of Patten et al.  (31) and BeUio et al.  (32) 
regarding bSAG recognition,  and with the data ofPullen et 
al. (2)  and Cazenave et al. (4) regarding vSAG recognition. 
In addition,  Thibodeau et al. (35) showed that binding sites 
for vSAGs and bSAGs are different in MHC  class  II mole- 
cules, suggesting two independent  SAG recogntion sites on 
the TCR. 
There  are many reports  that show  that different bSAGs 
(e.g.,  TSST-1,  SEA,  SEB)  bind to different regions  of the 
MHC  class II molecule (36-39).  Since all of these SAGs are 
recognized by various TCR  V~ domains, they are likely to 
be recognized in many different TCR-MHC  orientations. 
Thus,  it is not reasonable  to expect that a general orienta- 
tion  of the  TCR  to  its  MHC-peptide  ligand  can  be  de- 
duced  from  responses  to  bSAGs.  It  has  also  been  shown 
that  different  mutant  MHC  molecules  affect antigen  pre- 
sentation  and  presentation  of the  bSAG,  SEA,  to  T  cells 
differently (40). 
Recently,  Hamad et al.  (41)  showed that SEB presented 
by  a  plate-bound  anti-SEB  mAb  can  stimulate  T  cells  in 
the absence of MHC  class II molecules.  In addition,  a Bia- 
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TCR-SEB  interaction.  Some  bSAGs,  such  as  SEC  and 
SEE,  can  stimulate  T  cells using  MHC  class  II-negative 
APCs  (43).  All these  data suggest  that  bSAG can  directly 
stimulate the T  cell without need of a direct interaction of 
the  TCR.  with  MHC  class II molecules.  By  contrast,  no 
comparable observations on  binding of Mtv-7  have  been 
obtained (44). 
In  conclusion,  our  studies  show  that  residue  24  of the 
TCR,  [3  chain accounts  for a  contact with  the vSAG en- 
coded by  Mtv-7.  In  addition,  we  find  that  mutations  in 
CDR2  of V[3,  especially that  at  residue  51,  disrupt  SEB 
recognition without affecting responses to the vSAG Mtv-7 
or alloantigen recognition. It is perhaps most surprising that 
the double mutant  of V[3,  G51V,G53D,  responds to  SEB 
and  to  high  doses  of SEC1,  but  still lacks  a  response  to 
SEC2  and  SEC3.  In  addition,  a  transfectant  expressing  a 
single amino acid mutation in V[3,  G53D,  responds better 
than wild-type to  SEB  and  SEC1,  and responds normally 
to SEC2 and SEC3 (Fig. 5). Thus, whereas we can make a 
model for bSAG interaction with this TCR,  it is clear that 
this model will have to be complex. 
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